The viability of Jurkat cells treated with increasing amounts of hHis6FasL in the presence of 10 µg/ml anti-His antibody was assessed. After 24 hour treatment with hHis6FasL, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
The purity of recombinant hHis6FasL was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hHis6FasL and staining overnight with Coomassie Blue.
Treatment of Jurkat cells with hHis6FasL induces casapase-3 cleavage as detected by PathScan® Cleaved Caspase-3 (Asp175) Sandwich ELISA Kit #7190.
Western blot analysis of extracts from Jurkat cells, untreated or treated with hHis6FasL for 3 hours, using Cleaved PARP (Asp214) Antibody (Human Specific) #9541 (upper) or PARP Antibody #9542 (lower).
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hHis6FasL. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2
Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hHis6FasL. All lots are greater than 98% pure.
Recombinant N-terminally His6-tagged hFasL has a calculated MW of 19,834. DTT-reduced and non-reduced protein migrate as 31-36 kDa polypeptides. Lower mobility in SDS-PAGE is due to glycosylation.
Recombinant humanHis6 FasL (hHis6FasL) Pro134-Leu281 (Accession #NP_000630) was expressed in human 293 cells at Cell Signaling Technology.
FasL is a member of the TNF-superfamily family of proteins and is expressed primarily on the cell surface of activated T and NK cells (1). FasL regulates the immune response through its ability to induce apoptosis. The immunoregulatory role of FasL is underscored by lymphoadenopathy associated with FasL or Fas knockout mice and the fraction of autoimmune lympho-proliferative syndrome (ALPS) patients that have mutations in the FasL receptor, Fas (1). FasL is a membrane protein that can be cleaved into a soluble trimeric form by metalloproteinases (1,2). The soluble form of FasL retains the ability to bind to Fas, however, its ability to induce apoptosis is diminished (2). The ligation of Fas by FasL leads to the assembly of death-inducing signaling complex (DISC) and the recruitment and activation of caspase-8/caspase-10 (1,3). Active caspase-8/caspase-10 subsequently activates the “effector” caspases caspase-3 and caspase-7, and cleavage of BID (1,3).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
|5452SC||10 µg (With Carrier)||$ 221|
|5452SF||10 µg (Carrier Free)||$ 221|
Our US office is closed in observance of Thanksgiving. We will reopen on Monday, November 30th.
Thank you for your patience.